Journal List > J Korean Assoc Oral Maxillofac Surg > v.38(5) > 1091685

Karfeld-Sulzer and Weber: Biomaterial development for oral and maxillofacial bone regeneration

Abstract

Many oral and maxillofacial bone defects are not self-healing. Guided bone regeneration (GBR), which uses a barrier membrane to prevent the soft tissues from invading the defect to enable slower-growing bone cells to penetrate the area, was developed as a therapy in the 1980s. Although there has been some success with GBR in some clinical situations, better treatments are needed. This review discusses the concept of GBR focusing on bioactive membranes that incorporate osteoconductive materials, growth factors and cells for improved oral and maxillofacial bone regeneration.

I. Introduction

Facial trauma, bone resection due to cancer, periodontal disease, and bone atrophy after tooth extraction may leave non-self-healing oral and maxillofacial bone defects1. Although there is an inherent self-repair potential, a non-union remains for bone gaps greater than 25 mm or even only 500 µm, depending on the location, vascularization, and the mechanics2. The presence of infection or inflammation is another determining factor for bone regeneration capability at a given site. For the alveolar bone in particular, periodontitis, advanced periodontal disease that affects around 15% of adult humans, induces the destruction of the alveolar bone around teeth and can cause them to fall out3,4. Without the mechanical stimulus from teeth, alveolar bone naturally further degrades4,5. Interventions with tooth implants are additionally complicated since sufficient quantity and quality of the alveolar bone must be present to stabilize the implant6. Peri-implantitis, infection and inflammation around tooth implants, can have the same detrimental effects on the alveolar bone that periodontitis has on natural teeth.
As discussed by Mikos et al.7, there are some unique challenging aspects of tissue regeneration in oral and maxillofacial tissues. The irregular architecture and necessary precision of positioning the biomaterial replacements suggest injectable or moldable substitutes. Implants need sufficient mechanical properties and appropriate resorption rates that coordinate with tissue ingrowth. Moreover, the environment of the oral cavity with its flora presents additional complications for alveolar bone engineering.
Despite these challenges, guided bone regeneration (GBR) was developed and has served as a treatment since the 1980s for restoring osseous maxillofacial tissues8,9. An excellent overview on this subject was provided by Buser10. Through the use of a barrier membrane, this therapeutic strategy physically excludes ineffective soft tissue cells to allow osteoprogenitor cells to populate the area. Since its initial conception, the GBR membranes have progressed from non-resorbable to resorbable to bioactive occlusive materials. GBR has been shown to reliably close critical size periodontal defects and can even support neo-osteogenesis, bone growth extending past the original boundaries11. Although there has been success with GBR in various clinical situations, others, particularly alveolar ridge augmentation combined with implant placement, require further research to improve outcomes11. Thus, research on advanced materials, growth factor incorporation, and the inclusion of cells is ongoing to improve GBR for oral and maxillofacial bone regeneration.

II. Guided Bone Regeneration

1. Concept and requirements

GBR gained traction as a therapy in the 1980s, but in 1957 there was already an initial report of space creation with plastic cages for bone regeneration in femoral defects in dogs12. Other studies followed, including those focusing on the craniofacial area13,14, but the mechanism of action was initially hypothesized to be the protection of the blood clot. In the early 1980s, the guided tissue regeneration principle was established, explaining that a specific tissue can be rege ne rated when cells with the restorative ability for that tissue type are able to occupy the wound space9,15. Through space maintenance and the preclusion of faster growing cells from the gingival connective tissue and oral mucosal epithelium, osteogenic cells are allowed to infiltrate and form bone8,9,15-17.
By enabling new bone formation, GBR may obviate the use of autologous bone grafts. Although an excellent source, the use of autogenous tissue is not desirable due to the pain and morbidity associated with the graft harboring site4,18. To function properly, GBR membranes must meet certain requirements, including cell exclusion, space creation, scaffolding for progenitor cell in-growth, biocompatibility, host tissue integration, and clinical manageability1,11,17.

2. Non-resorbable and resorbable membranes

The first generation of barrier membranes was non-resorbable, with expanded polytetrafluorothylene (ePTFE) (Teflon; Gore, Flagstaff, AZ, USA) membranes becoming the most frequently used1,8,11. With its high stability, non-immunogenicity, and reliably successful results, ePTFE membranes have been considered a gold standard for bone regeneration11,19, despite the fact that ePTFE-membrane exposure to the oral cavity always resulted in a failure of the treatment.
Even with the favorable outcomes using non-resorbable ePTFE, the strong disadvantage of requiring a second surgery to remove the material encouraged the development of a second generation of GBR with degradable barrier membranes. Along with the morbidity associated with a second surgical procedure for non-resorbable membrane removal, there is a risk of tissue damage and disturbed healing19. Additionally, there are some post-surgical complications of membrane exposure with non-biodegradable membranes that lead to a high incidence of infection that can decrease bone regeneration20,21. Besides avoiding the second surgery, resorbable membranes are also advantageous because of improved soft tissue healing and lower bacterial contamination risk due to decreased exposure from the degrading membrane19. In addition to the requirements stated previously, there are also further properties that these barrier membranes must fulfill: biocompatible degradation products that don't interfere with bone regeneration, appropriate degradation profile to synchronize with new tissue growth, and sufficient persistent mechanical and physical properties to perform the barrier function and allow in vivo use3.
Amongst the most common bioresorbable membranes are synthetic polyesters (poly(lactic acid), poly(glycolic acid), and poly(caprolactone) and their copolymers)22-25 and tissue-derived collagen21,26-29. Polyester membranes display biocompatibility and possess a high degree of customization, with degradation rates and mechanical properties that can be adjusted based on polymer composition and concentration30,31. As a natural component of the extracellular matrix, collagen is biocompatible and cell adhesive. Although collagen isn't inherently mechanically stable, it can be modified through various means of crosslinking3. Poly(ethylene glycol) (PEG) is also known as a biodegradable and biocompatible polymer. Since many oral and maxillofacial defects require precise shapes, an injectable material is desirable, such as a PEG-based in situ forming gel for GBR that demonstrated effectiveness in a clinical trial32-34.
In addition to the type of material, the physical form also plays a role in determining a material's properties, which can affect degradation rates and tissue integration. Porosity is one of the most important characteristics. With some materials, such as poly(lactide-co-glycolide), the porosity can be imposed by using porogens that form the pores and then are removed in a subsequent processing step35. Electrospinning is a manufacturing technique that creates elongated fibers with a degree of control over properties including fiber length, width, and orientation and overall porosity3. Researchers have explored these techniques for improving GBR membranes.
Although the existing bioresorbable membranes fulfill many requirements, most of them cannot maintain adequate space to act as a barrier membrane over an extended period of time5,19. However, in combination with a bone substitute material, these composite membranes have shown success24.

III. Bioactive Membranes

In addition to providing mechanical support to resorbable GBR membranes, the inclusion of bone substitute materials can render a membrane bioactive. Current research aims to develop a third generation of GBR membranes that are not only occlusive and degradable, but also contain bioactivity to biologically stimulate osteoprogenitor cells for enhanced bone growth. Using tissue engineering principles, advanced materials with the incorporation of bioactive molecules and cells are being explored for the development of the next generation of membranes. Instead of simply maintaining a space for osteoprogenitor ingrowth, the critical aspects of the natural environment are being recapitulated.

1. Bone graft materials

Effective bone graft materials can biologically stimulate bone growth through either osteoconduction by allowing cell growth through a scaffolding mechanism or osteoinduction by recruiting osteoprogenitors into the defect space4. Although cancellous autogenous bone grafts act as an osteoconductive material, the associated morbidity of the graft site restricts its use. Other natural sources include both allografts and xenografts, which are processed to reduce immunogenicity36. Demineralized bovine bone matrix retains type-1 collagen, non-collagenous proteins as well as a small amount of osteoinductive growth factors37. One of the most common commercially used products is deproteinized bovine bone matrix, Bio-Oss (Geistlich Biomaterials, Wolhusen, Switzerland), which is stripped of all organic elements by pyrolysis, a high temperature sintering, leaving hydroxyapatite (HA) as the main component38. Unfortunately, high temperature sintering also affects HA and alters it from a biological HA to a more synthetic one39. Despite positive outcomes of naturally-derived materials, there are still concerns regarding disease transmission and immunogenicity4.
Synthetic graft materials supply various formulations of calcium phosphate without the limitations of the animal-derived products. Bone is composed of a majority of calcium phosphate and these synthetic substitutes are known to have biologically active surface chemistry for osseointegration40. Additionally, these biodegradable, inorganic materials have a crystallographic structure similar to bone and controllable porosity that is important for mimicking bone, making them effective substitutes41,42. HA has been utilized as granules42,43, incorporated as nanoparticles3, or as a coating44. Tricalcium phosphate (TCP), which resorbs faster than HA, is another commonly used inorganic bone substitute41,45. Bioactive glass is another inorganic bone graft material that displays osteoconduction and an ability to bond with bone through chemical linkages46,47.

2. Growth factors

Membranes and graft materials can act as a barrier to fibrous tissue ingrowth and a scaffold to support bone and some even provide some osteoinductive activity, but a further critical role of biomaterials in improving oral and maxillofacial bone regeneration is delivering bioactive molecules. Growth factors are signaling proteins that regulate cellular growth, proliferation, and differentiation. Enamel matrix derivative and platelet rich plasma are both biologically-derived products that contain multiple growth factors and have demonstrated enhanced healing in periodontal tissues even though the mechanism of action is not understood3,48,49. Platelet rich plasma is comprised of various autologous growth factors that have individually been identified to enhance bone regeneration, including platelet-derived growth factor50, fibroblast growth factor51, and insulin-like growth factor52, but its positive effect on regeneration processes appears to be restricted to soft tissue healing49,53.
The class of bone morphogenetic proteins (BMPs), first identified to generate extraskeletal bone formation in bone extracts in 196554, have now been extensively studied and shown to be critical for the induction of bone55. The class of BMPs consists of 15 variants, with BMP-2, BMP-4, BMP-7, and BMP-12 shown to be particularly effective in bone regeneration56. BMP-2 and BMP-7 have been recombinantly produced for commercial use45. BMP-2 has shown impressive potential to regenerate bone in animal studies and the clinic, including in oral applications57. GBR in conjunction with BMP-2 delivery by a bone substitute material has been shown to be an effective strategy in humans as well58. However, milligram doses that are orders of magnitude higher than normal physiological levels are required59. An enhancer of BMP-2, such as N-methyl pyrrolidone (NMP), can possibly avoid the high cost and possible side effects and safety concerns of the large dose60. In a rabbit calvarial model, NMP enhanced bone regeneration over a polylactide membrane alone, emphasizing the importance of the bioactivity61.
Besides enhancers, controlled release of growth factors can increase their efficiency. In fact, acting as a vehicle for local delivery of growth factors and protecting them from degradation and inactivation are major roles of biomaterials. A slow, controlled release BMP-2 delivery system has been shown to induce and sustain bone formation62. Many of the same materials used as bone grafts have also been explored as delivery systems: collagen63, calcium phosphates64, and polyesters like polycaprolactone65.
Growth factors can non-covalently bind or covalently attach to the carrier66. Non-covalent growth factor delivery systems can function through adsorption (e.g., collagen sponge63 and deproteinized bovine bone matrix38), ion complexation with charged polymers (e.g., poly-L-ornithine and poly-L-arginine complexes67) or physical entrapment (e.g., polyesters68 and PEG38). The materials that physically incorporate growth factors can take various forms from liposomes69 to nanoparticles70 to hydrogels71. In contrast to these modes of delivery, covalent systems retain growth factors at the site of action until cleaved off or the carrier is degraded, extending the residence time66. Additionally, immobilization enables spatial growth factor delivery, limits side effects by constraining the growth factors to the site of action, and mimics physiological matrix-bound situations72. Growth factors can be covalently tethered to a material directly73,74 or through a linker75,76. Another strategy is genetically engineering fusion growth factors that include an attachment site outside the active protein sequence. BMP-2 was engineered to contain amino acid domains that enable both enzymatic covalent attachment to and release from fibrin-based substances, creating a system that mimics physiological binding and liberation77. Although it is possible that the growth factor may lose some activity through all of these covalent immobilization methods, this loss may be mitigated by the higher retention and other advantages.

3. Cells

In addition to allowing the delivery of bioactive molecules, biomaterials are also critical for enabling cell-based therapies. To encourage proliferation and differentiation, cells require an artificial extracellular matrix, which can be supplied through an appropriately designed biomaterial36. Including a cell source can further encourage oral and maxillofacial bone growth through direct tissue growth and bone repair as well as growth factor secretion from the cells78. Although this area has only been actively pursued relatively recently, due to advancements in biological cell research, there are some promising studies.
Mesenchymal stem cells (MSCs), multipotent adult stem cells that can be harvested from mesenchymal tissues such as bone marrow, have been suggested as a cell source for tissue engineering56. Since they are easily attained and expanded, bone marrow MSCs (BMSCs) are the most commonly explored MSCs36. A number of studies have demonstrated alveolar bone regeneration with BMSCs79-81. A study also showed the positive effect of combining stem cells with growth factor release through BMP-2 expressing BMSCs82.
In addition to BMSCs, there are several other cell types that are being explored for oral and maxillofacial bone tissue engineering. Umbilical cord MSCs are another easily obtainable reservoir of stem cells and initial studies show promising results for bone regeneration with this source83-86. Adipose-derived stem cells are other extraoral and non-craniofacial cells that are easily accessible and were successfully used to regenerate bone87,88. The periodontal ligament and dental pulp are both sources of stem cells in the oral cavity that have been isolated and characterized56,89. Stem cells from both of these tissues have demonstrated bone regeneration capabilities90-92. However, these cells are more difficult to harvest36.
With all of these stem cells sources, the biomaterial that supports them is a critical aspect for facilitating bone regeneration. Many of the same materials that have been developed as bone graft materials and bioactive molecule delivery vehicles have been explored as cell scaffolds. HA93, collagen94, fibrin87, and poly(lactide-co-glycolide)95 as well as composites such as HA/TCP96, chitosan-gelatin79, and calcium phosphate cement-chitosan-polyglactin86 are amongst these scaffolds.

IV. Conclusion

The field of bone regeneration for oral and maxillofacial tissues has progressed dramatically from the first non-resorbable GBR membranes to bioactive materials. Guided by tissue engineering principles, there is a large amount of current research on designing membranes consisting of bioactive materials that can deliver growth factors and cells. Future improvements will require appropriate combinations of materials, growth factors and cells that permit temporal and spatial growth factor release, suitable degradation profiles that both allow tissue ingrowth and maintain sufficient occlusivity, and positive mimicking of the extracellular matrix to support and encourage cell proliferation and differentiation. Composite materials, multilayered constructs, and varying physical forms are amongst the possible strategies in biomaterial development for this ongoing body of research.

References

1. Hitti RA, Kerns DG. Guided bone regeneration in the oral cavity: a review. Open Pathol J. 2011. 5:33–45.
crossref
2. Johner R. Dependence of bone healing on defect size. Helv Chir Acta. 1972. 39:409–411.
3. Bottino MC, Thomas V, Schmidt G, Vohra YK, Chu TM, Kowolik MJ, et al. Recent advances in the development of GTR/GBR membranes for periodontal regeneration--a materials perspective. Dent Mater. 2012. 28:703–721.
crossref
4. Hughes FJ, Ghuman M, Talal A. Periodontal regeneration: a challenge for the tissue engineer? Proc Inst Mech Eng H. 2010. 224:1345–1358.
crossref
5. Hämmerle CH, Karring T. Guided bone regeneration at oral implant sites. Periodontol 2000. 1998. 17:151–175.
crossref
6. Araujo MG, Lindhe J. Dimensional ridge alterations following tooth extraction. An experimental study in the dog. J Clin Periodontol. 2005. 32:212–218.
crossref
7. Mikos AG, Herring SW, Ochareon P, Elisseeff J, Lu HH, Kandel R, et al. Engineering complex tissues. Tissue Eng. 2006. 12:3307–3339.
crossref
8. Dahlin C, Linde A, Gottlow J, Nyman S. Healing of bone defects by guided tissue regeneration. Plast Reconstr Surg. 1988. 81:672–676.
crossref
9. Nyman S, Lindhe J, Karring T, Rylander H. New attachment following surgical treatment of human periodontal disease. J Clin Periodontol. 1982. 9:290–296.
crossref
10. Buser D. 20 years of guided bone regeneration in implant dentistry. 2009. 2nd ed. Berlin: Quintessence.
11. Retzepi M, Donos N. Guided Bone Regeneration: biological principle and therapeutic applications. Clin Oral Implants Res. 2010. 21:567–576.
crossref
12. Murray G, Holden R, Roschlau W. Experimental and clinical study of new growth of bone in a cavity. Am J Surg. 1957. 93:385–387.
crossref
13. Kahnberg KE. Restoration of mandibular jaw defects in the rabbit by subperiosteally implanted Teflon mantle leaf. Int J Oral Surg. 1979. 8:449–456.
crossref
14. Melcher AH. Role of the periosteum in repair of wounds of the parietal bone of the rat. Arch Oral Biol. 1969. 14:1101–1109.
crossref
15. Karring T, Nyman S, Lindhe J. Healing following implantation of periodontitis affected roots into bone tissue. J Clin Periodontol. 1980. 7:96–105.
crossref
16. Gottlow J, Nyman S, Karring T, Lindhe J. New attachment formation as the result of controlled tissue regeneration. J Clin Periodontol. 1984. 11:494–503.
crossref
17. Karring T, Nyman S, Gottlow J, Laurell L. Development of the biological concept of guided tissue regeneration--animal and human studies. Periodontol 2000. 1993. 1:26–35.
crossref
18. McAllister BS, Haghighat K. Bone augmentation techniques. J Periodontol. 2007. 78:377–396.
crossref
19. Hammerle CH, Jung RE. Bone augmentation by means of barrier membranes. Periodontol 2000. 2003. 33:36–53.
crossref
20. Murphy KG. P. Int J Periodontics Restorative Dent. 1995. 15:363–375.
21. Wang HL, Carroll MJ. Guided bone regeneration using bone grafts and collagen membranes. Quintessence Int. 2001. 32:504–515.
22. Gentile P, Chiono V, Tonda-Turo C, Ferreira AM, Ciardelli G. Polymeric membranes for guided bone regeneration. Biotechnol J. 2011. 6:1187–1197.
crossref
23. Geurs NC, Korostoff JM, Vassilopoulos PJ, Kang TH, Jeffcoat M, Kellar R, et al. Clinical and histologic assessment of lateral alveolar ridge augmentation using a synthetic long-term bioabsorbable membrane and an allograft. J Periodontol. 2008. 79:1133–1140.
crossref
24. Sculean A, Nikolidakis D, Schwarz F. Regeneration of periodontal tissues: combinations of barrier membranes and grafting materials-biological foundation and preclinical evidence: a systematic review. J Clin Periodontol. 2008. 35:8 Suppl. 106–116.
crossref
25. Milella E, Barra G, Ramires PA, Leo G, Aversa P, Romito A. Poly(L-lactide)acid/alginate composite membranes for guided tissue regeneration. J Biomed Mater Res. 2001. 57:248–257.
crossref
26. Tal H, Kozlovsky A, Artzi Z, Nemcovsky CE, Moses O. Cross-linked and non-cross-linked collagen barrier membranes disintegrate following surgical exposure to the oral environment: a histological study in the cat. Clin Oral Implants Res. 2008. 19:760–766.
crossref
27. Parodi R, Carusi G, Santarelli G, Nanni F. Implant placement in large edentulous ridges expanded by GBR using a bioresorbable collagen membrane. Int J Periodontics Restorative Dent. 1998. 18:266–275.
28. Colangelo P, Piattelli A, Barrucci S, Trisi P, Formisano G, Caiazza S. Bone regeneration guided by resorbable collagen membranes in rabbits: a pilot study. Implant Dent. 1993. 2:101–105.
29. Coïc M, Placet V, Jacquet E, Meyer C. Mechanical properties of collagen membranes used in guided bone regeneration: a comparative study of three models. Rev Stomatol Chir Maxillofac. 2010. 111:286–290.
30. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011. 3:1377–1397.
crossref
31. Vert M. Aliphatic polyesters: great degradable polymers that cannot do everything. Biomacromolecules. 2005. 6:538–546.
crossref
32. Jung RE, Halg GA, Thoma DS, Hammerle CH. A randomized, controlled clinical trial to evaluate a new membrane for guided bone regeneration around dental implants. Clin Oral Implants Res. 2009. 20:162–168.
crossref
33. Jung RE, Zwahlen R, Weber FE, Molenberg A, van Lenthe GH, Hammerle CH. Evaluation of an in situ formed synthetic hydrogel as a biodegradable membrane for guided bone regeneration. Clin Oral Implants Res. 2006. 17:426–433.
crossref
34. Wechsler S, Fehr D, Molenberg A, Raeber G, Schense JC, Weber FE. A novel, tissue occlusive poly(ethylene glycol) hydrogel material. J Biomed Mater Res A. 2008. 85:285–292.
crossref
35. Amini AR, Adams DJ, Laurencin CT, Nukavarapu SP. Optimally porous and biomechanically compatible scaffolds for large-area bone regeneration. Tissue Eng Part A. 2012. 18:1376–1388.
crossref
36. Chen FM, Jin Y. Periodontal tissue engineering and regeneration: current approaches and expanding opportunities. Tissue Eng Part B Rev. 2010. 16:219–255.
crossref
37. Calori GM, Mazza E, Colombo M, Ripamonti C. The use of bone-graft substitutes in large bone defects: any specific needs? Injury. 2011. 42:Suppl 2. S56–S63.
crossref
38. Hanseler P, Jung UW, Jung RE, Choi KH, Cho KS, Hammerle CH, et al. Analysis of hydrolyzable polyethylene glycol hydrogels and deproteinized bone mineral as delivery systems for glycosylated and non-glycosylated bone morphogenetic protein-2. Acta Biomater. 2012. 8:116–123.
crossref
39. Henkel KO, Gerber T, Lenz S, Gundlach KK, Bienengraber V. Macroscopical, histological, and morphometric studies of porous bone-replacement materials in minipigs 8 months after implantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006. 102:606–613.
crossref
40. Palarie V, Bicer C, Lehmann KM, Zahalka M, Draenert FG, Kammerer PW. Early outcome of an implant system with a resorbable adhesive calcium-phosphate coating--a prospective clinical study in partially dentate patients. Clin Oral Investig. 2012. 16:1039–1048.
crossref
41. Hannink G, Arts JJ. Bioresorbability, porosity and mechanical strength of bone substitutes: what is optimal for bone regeneration? Injury. 2011. 42:Suppl 2. S22–S25.
crossref
42. Kruse A, Jung RE, Nicholls F, Zwahlen RA, Hammerle CH, Weber FE. Bone regeneration in the presence of a synthetic hydroxyapatite/silica oxide-based and a xenogenic hydroxyapatite-based bone substitute material. Clin Oral Implants Res. 2011. 22:506–511.
crossref
43. Qu Y, Wang P, Man Y, Li Y, Zuo Y, Li J. Preliminary biocompatible evaluation of nano-hydroxyapatite/polyamide 66 composite porous membrane. Int J Nanomedicine. 2010. 5:429–435.
crossref
44. Kamitakahara M, Ohtsuki C, Miyazaki T. Coating of bone-like apatite for development of bioactive materials for bone reconstruction. Biomed Mater. 2007. 2:R17–R23.
crossref
45. Darby I. Periodontal materials. Aust Dent J. 2011. 56:Suppl 1. 107–118.
crossref
46. San Miguel B, Kriauciunas R, Tosatti S, Ehrbar M, Ghayor C, Textor M, et al. Enhanced osteoblastic activity and bone regeneration using surface-modified porous bioactive glass scaffolds. J Biomed Mater Res A. 2010. 94:1023–1033.
47. Mota J, Yu N, Caridade SG, Luz GM, Gomes ME, Reis RL, et al. Chitosan/bioactive glass nanoparticle composite membranes for periodontal regeneration. Acta Biomater. 2012. 8:4173–4180.
crossref
48. Grandin HM, Gemperli AC, Dard M. Enamel matrix derivative: a review of cellular effects in vitro and a model of molecular arrangement and functioning. Tissue Eng Part B Rev. 2012. 18:181–202.
crossref
49. Nikolidakis D, Jansen JA. The biology of platelet-rich plasma and its application in oral surgery: literature review. Tissue Eng Part B Rev. 2008. 14:249–258.
crossref
50. Thoma DS, Jung RE, Hanseler P, Hammerle CH, Cochran DL, Weber FE. Impact of recombinant platelet-derived growth factor BB on bone regeneration: a study in rabbits. Int J Periodontics Restorative Dent. 2012. 32:195–202.
51. Hong KS, Kim EC, Bang SH, Chung CH, Lee YI, Hyun JK, et al. Bone regeneration by bioactive hybrid membrane containing FGF2 within rat calvarium. J Biomed Mater Res A. 2010. 94:1187–1194.
crossref
52. Kang H, Sung J, Jung HM, Woo KM, Hong SD, Roh S. Insulin-like growth factor 2 promotes osteogenic cell differentiation in the parthenogenetic murine embryonic stem cells. Tissue Eng Part A. 2012. 18:331–341.
crossref
53. Jung RE, Schmoekel HG, Zwahlen R, Kokovic V, Hammerle CH, Weber FE. Platelet-rich plasma and fibrin as delivery systems for recombinant human bone morphogenetic protein-2. Clin Oral Implants Res. 2005. 16:676–682.
crossref
54. Urist MR. Bone: formation by autoinduction. Science. 1965. 150:893–899.
crossref
55. Ripamonti U, Reddi AH. Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins. Crit Rev Oral Biol Med. 1997. 8:154–163.
crossref
56. Elangovan S, Srinivasan S, Ayilavarapu S. Novel regenerative strategies to enhance periodontal therapy outcome. Expert Opin Biol Ther. 2009. 9:399–410.
crossref
57. Wikesjo UM, Qahash M, Huang YH, Xiropaidis A, Polimeni G, Susin C. Bone morphogenetic proteins for periodontal and alveolar indications; biological observations-clinical implications. Orthod Craniofac Res. 2009. 12:263–270.
58. Jung RE, Glauser R, Scharer P, Hammerle CH, Sailer HF, Weber FE. Effect of rhBMP-2 on guided bone regeneration in humans. Clin Oral Implants Res. 2003. 14:556–568.
crossref
59. Zhu W, Kim J, Cheng C, Rawlins BA, Boachie-Adjei O, Crystal RG, et al. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone. 2006. 39:61–71.
crossref
60. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011. 11:471–491.
crossref
61. Miguel BS, Ghayor C, Ehrbar M, Jung RE, Zwahlen RA, Hortschansky P, et al. N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. Tissue Eng Part A. 2009. 15:2955–2963.
crossref
62. Hunziker EB, Enggist L, Kuffer A, Buser D, Liu Y. Osseointegration: the slow delivery of BMP-2 enhances osteoinductivity. Bone. 2012. 51:98–106.
crossref
63. Herford AS, Boyne PJ. Reconstruction of mandibular continuity defects with bone morphogenetic protein-2 (rhBMP-2). J Oral Maxillofac Surg. 2008. 66:616–624.
crossref
64. Jung RE, Weber FE, Thoma DS, Ehrbar M, Cochran DL, Hammerle CH. Bone morphogenetic protein-2 enhances bone formation when delivered by a synthetic matrix containing hydroxyapatite/tricalciumphosphate. Clin Oral Implants Res. 2008. 19:188–195.
crossref
65. Boerckel JD, Kolambkar YM, Dupont KM, Uhrig BA, Phelps EA, Stevens HY, et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials. 2011. 32:5241–5251.
crossref
66. Luginbuehl V, Meinel L, Merkle HP, Gander B. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm. 2004. 58:197–208.
crossref
67. Abbah SA, Liu J, Lam RW, Goh JC, Wong HK. In vivo bioactivity of rhBMP-2 delivered with novel polyelectrolyte complexation shells assembled on an alginate microbead core template. J Control Release. 2012. 162:364–372.
crossref
68. Zellin G, Linde A. Importance of delivery systems for growth-stimulatory factors in combination with osteopromotive membranes. An experimental study using rhBMP-2 in rat mandibular defects. J Biomed Mater Res. 1997. 35:181–190.
crossref
69. Matsuo T, Sugita T, Kubo T, Yasunaga Y, Ochi M, Murakami T. Injectable magnetic liposomes as a novel carrier of recombinant human BMP-2 for bone formation in a rat bone-defect model. J Biomed Mater Res A. 2003. 66:747–754.
crossref
70. Machado R, Bessa PC, Reis RL, Rodriguez-Cabello JC, Casal M. Elastin-based nanoparticles for delivery of bone morphogenetic proteins. Methods Mol Biol. 2012. 906:353–363.
crossref
71. Bulpitt P, Aeschlimann D. New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels. J Biomed Mater Res. 1999. 47:152–169.
crossref
72. Masters KS. Covalent growth factor immobilization strategies for tissue repair and regeneration. Macromol Biosci. 2011. 11:1149–1163.
crossref
73. Park J, Bauer S, Pittrof A, Killian MS, Schmuki P, von der Mark K. Synergistic control of mesenchymal stem cell differentiation by nanoscale surface geometry and immobilized growth factors on TiO2 nanotubes. Small. 2012. 8:98–107.
crossref
74. Yamachika E, Tsujigiwa H, Shirasu N, Ueno T, Sakata Y, Fukunaga J, et al. Immobilized recombinant human bone morphogenetic protein-2 enhances the phosphorylation of receptor-activated Smads. J Biomed Mater Res A. 2009. 88:599–607.
crossref
75. Park YJ, Kim KH, Lee JY, Ku Y, Lee SJ, Min BM, et al. Immobilization of bone morphogenetic protein-2 on a nanofibrous chitosan membrane for enhanced guided bone regeneration. Biotechnol Appl Biochem. 2006. 43:17–24.
crossref
76. Zhang H, Migneco F, Lin CY, Hollister SJ. Chemically-conjugated bone morphogenetic protein-2 on three-dimensional polycaprolactone scaffolds stimulates osteogenic activity in bone marrow stromal cells. Tissue Eng Part A. 2010. 16:3441–3448.
crossref
77. Schmoekel HG, Weber FE, Schense JC, Gratz KW, Schawalder P, Hubbell JA. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng. 2005. 89:253–262.
crossref
78. Rios HF, Lin Z, Oh B, Park CH, Giannobile WV. Cell- and gene-based therapeutic strategies for periodontal regenerative medicine. J Periodontol. 2011. 82:1223–1237.
crossref
79. Miranda SC, Silva GA, Mendes RM, Abreu FA, Caliari MV, Alves JB, et al. Mesenchymal stem cells associated with porous chitosan-gelatin scaffold: A potential strategy for alveolar bone regeneration. J Biomed Mater Res A. 2012. 100:2775–2786.
crossref
80. Hasegawa N, Kawaguchi H, Hirachi A, Takeda K, Mizuno N, Nishimura M, et al. Behavior of transplanted bone marrow-derived mesenchymal stem cells in periodontal defects. J Periodontol. 2006. 77:1003–1007.
crossref
81. Li H, Yan F, Lei L, Li Y, Xiao Y. Application of autologous cryopreserved bone marrow mesenchymal stem cells for periodontal regeneration in dogs. Cells Tissues Organs. 2009. 190:94–101.
crossref
82. Chung VH, Chen AY, Kwan CC, Chen PK, Chang SC. Mandibular alveolar bony defect repair using bone morphogenetic protein 2-expressing autologous mesenchymal stem cells. J Craniofac Surg. 2011. 22:450–454.
crossref
83. Thein-Han W, Liu J, Xu HH. Calcium phosphate cement with biofunctional agents and stem cell seeding for dental and craniofacial bone repair. Dent Mater. 2012. 28:1059–1070.
crossref
84. Wang B, Huang S, Pan L, Jia S. Enhancement of bone formation by genetically engineered human umbilical cord-derived mesenchymal stem cells expressing osterix. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012. 07. 19. [Epub ahead of print].
crossref
85. Wen Y, Jiang B, Cui J, Li G, Yu M, Wang F, et al. Superior osteogenic capacity of different mesenchymal stem cells for bone tissue engineering. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012. 07. 26. [Epub ahead of print].
crossref
86. Zhao L, Burguera EF, Xu HH, Amin N, Ryou H, Arola DD. Fatigue and human umbilical cord stem cell seeding characteristics of calcium phosphate-chitosan-biodegradable fiber scaffolds. Biomaterials. 2010. 31:840–847.
crossref
87. Lendeckel S, Jodicke A, Christophis P, Heidinger K, Wolff J, Fraser JK, et al. Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. J Craniomaxillofac Surg. 2004. 32:370–373.
crossref
88. Mesimaki K, Lindroos B, Tornwall J, Mauno J, Lindqvist C, Kontio R, et al. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells. Int J Oral Maxillofac Surg. 2009. 38:201–209.
crossref
89. Liu H, Gronthos S, Shi S. Dental pulp stem cells. Methods Enzymol. 2006. 419:99–113.
crossref
90. Liu HC, E LL, Wang DS, Su F, Wu X, Shi ZP, et al. Reconstruction of alveolar bone defects using bone morphogenetic protein 2 mediated rabbit dental pulp stem cells seeded on nanohydroxyapatite/collagen/poly(L-lactide). Tissue Eng Part A. 2011. 17:2417–2433.
crossref
91. Liu Y, Zheng Y, Ding G, Fang D, Zhang C, Bartold PM, et al. Periodontal ligament stem cell-mediated treatment for periodontitis in miniature swine. Stem Cells. 2008. 26:1065–1073.
crossref
92. Park JY, Jeon SH, Choung PH. Efficacy of periodontal stem cell transplantation in the treatment of advanced periodontitis. Cell Transplant. 2011. 20:271–285.
crossref
93. Noshi T, Yoshikawa T, Ikeuchi M, Dohi Y, Ohgushi H, Horiuchi K, et al. Enhancement of the in vivo osteogenic potential of marrow/hydroxyapatite composites by bovine bone morphogenetic protein. J Biomed Mater Res. 2000. 52:621–630.
crossref
94. Niu LN, Jiao K, Qi YP, Nikonov S, Yiu CK, Arola DD, et al. Intrafibrillar silicification of collagen scaffolds for sustained release of stem cell homing chemokine in hard tissue regeneration. FASEB J. 2012. 08. 02. [Epub ahead of print].
crossref
95. Partridge K, Yang X, Clarke NM, Okubo Y, Bessho K, Sebald W, et al. Adenoviral BMP-2 gene transfer in mesenchymal stem cells: in vitro and in vivo bone formation on biodegradable polymer scaffolds. Biochem Biophys Res Commun. 2002. 292:144–152.
crossref
96. Vahabi S, Amirizadeh N, Shokrgozar MA, Mofeed R, Mashhadi A, Aghaloo M, et al. A comparison between the efficacy of Bio-Oss, hydroxyapatite tricalcium phosphate and combination of mesenchymal stem cells in inducing bone regeneration. Chang Gung Med J. 2012. 35:28–37.
crossref
TOOLS
Similar articles